114 related articles for article (PubMed ID: 28892793)
1. Homoisoflavonoids as potential antiangiogenic agents for retinal neovascularization.
Amin SA; Adhikari N; Gayen S; Jha T
Biomed Pharmacother; 2017 Nov; 95():818-827. PubMed ID: 28892793
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Biological Evaluation of Novel Homoisoflavonoids for Retinal Neovascularization.
Basavarajappa HD; Lee B; Lee H; Sulaiman RS; An H; Magaña C; Shadmand M; Vayl A; Rajashekhar G; Kim EY; Suh YG; Lee K; Seo SY; Corson TW
J Med Chem; 2015 Jun; 58(12):5015-5027. PubMed ID: 26035340
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factors in retinal and choroidal neovascular diseases.
Kinnunen K; Ylä-Herttuala S
Ann Med; 2012 Feb; 44(1):1-17. PubMed ID: 21284527
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of photoaffinity probes of antiangiogenic homoisoflavonoids.
Lee B; Sun W; Lee H; Basavarajappa H; Sulaiman RS; Sishtla K; Fei X; Corson TW; Seo SY
Bioorg Med Chem Lett; 2016 Sep; 26(17):4277-81. PubMed ID: 27481561
[TBL] [Abstract][Full Text] [Related]
5. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy.
Zhang SX; Ma JX
Prog Retin Eye Res; 2007 Jan; 26(1):1-37. PubMed ID: 17074526
[TBL] [Abstract][Full Text] [Related]
6. [Experience with vascular endothelial growth factor inhibitors used in ophthalmologic care].
Khalaim AV; Stoliarenko GE
Vestn Oftalmol; 2007; 123(5):54-6, preceding 56. PubMed ID: 18078062
[No Abstract] [Full Text] [Related]
7. Ranibizumab for retinal neovascularization.
Jorge R; Oliveira RS; Messias A; Almeida FP; Strambe ML; Costa RA; Scott IU
Ophthalmology; 2011 May; 118(5):1004-1004.e1. PubMed ID: 21539985
[No Abstract] [Full Text] [Related]
8. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
9. VEGF is clearly an exciting point of attack in the treatment of neovascular diseases of the retina and choroid.
Coimbra JC
Ophthalmologica; 2012; 227 Suppl 1():1. PubMed ID: 22645747
[No Abstract] [Full Text] [Related]
10. The Antiangiogenic Activity of Naturally Occurring and Synthetic Homoisoflavonoids from the Hyacinthaceae ( sensu APGII).
Schwikkard S; Whitmore H; Sishtla K; Sulaiman RS; Shetty T; Basavarajappa HD; Waller C; Alqahtani A; Frankemoelle L; Chapman A; Crouch N; Wetschnig W; Knirsch W; Andriantiana J; Mas-Claret E; Langat MK; Mulholland D; Corson TW
J Nat Prod; 2019 May; 82(5):1227-1239. PubMed ID: 30951308
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic revolution in the management of diabetic retinopathy.
Hurley B
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S1-S2. PubMed ID: 29074003
[No Abstract] [Full Text] [Related]
12. Intravitreal bevacizumab for peripapillary classic subretinal neovascularization.
Spandau UH; Jonas JB
Acta Ophthalmol Scand; 2007 May; 85(3):340-1. PubMed ID: 17488467
[No Abstract] [Full Text] [Related]
13. Volume Rendering of Optical Coherence Tomography Angiography Reveals Extensive Retinal Vascular Contributions to Neovascularization in Ocular Toxoplasmosis.
Spaide RF
Retina; 2015 Nov; 35(11):2421-2. PubMed ID: 26405767
[No Abstract] [Full Text] [Related]
14. Rapid regression of retinal neovascularization following intravitreal bevacizumab in branch retinal vein occlusion imaged by optical coherence tomography angiography.
Brar M; Grewal DS; Sharma M; Grewal SPS
Indian J Ophthalmol; 2018 Apr; 66(4):572. PubMed ID: 29582824
[No Abstract] [Full Text] [Related]
15. An evidence-based review of vascular endothelial growth factor inhibition in pediatric retinal diseases: part 2. Coats' disease, best disease, and uveitis with childhood neovascularization.
Chaudhary KM; Mititelu M; Lieberman RM
J Pediatr Ophthalmol Strabismus; 2013; 50(1):11-9. PubMed ID: 22938515
[TBL] [Abstract][Full Text] [Related]
16. Calcitriol is a potent inhibitor of retinal neovascularization.
Albert DM; Scheef EA; Wang S; Mehraein F; Darjatmoko SR; Sorenson CM; Sheibani N
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2327-34. PubMed ID: 17460298
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Potential of Small Molecules for Treating Corneal Neovascularization.
Barry Z; Park B; Corson TW
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751576
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy.
Siqueira RC; Costa RA; Scott IU; Cintra LP; Jorge R
Acta Ophthalmol Scand; 2006 Dec; 84(6):834-5. PubMed ID: 17083555
[No Abstract] [Full Text] [Related]
19. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab.
Kumar A; Sinha S
Can J Ophthalmol; 2007 Apr; 42(2):335-6. PubMed ID: 17392871
[No Abstract] [Full Text] [Related]
20. Acetyl-11-keto-β-boswellic acid reduces retinal angiogenesis in a mouse model of oxygen-induced retinopathy.
Lulli M; Cammalleri M; Fornaciari I; Casini G; Dal Monte M
Exp Eye Res; 2015 Jun; 135():67-80. PubMed ID: 25913458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
